Last reviewed · How we verify
Bacteremia caused by Staphylococcus aureus — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cubicin | Daptomycin | Baxter | lipopeptide antibacterial | 2003-01-01 | ||
| Cubicin | Cubicin | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | Outer membrane porin protein OmpD | |||
| DAPT | DAPT | Baxter Hlthcare Corp | Outer membrane porin protein OmpD |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 1 drug in Bacteremia caused by Staphylococcus aureus
- Baxter Hlthcare Corp · 1 drug in Bacteremia caused by Staphylococcus aureus
- Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Bacteremia caused by Staphylococcus aureus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Bacteremia caused by Staphylococcus aureus:
- Bacteremia caused by Staphylococcus aureus treatment updates — RSS
- Bacteremia caused by Staphylococcus aureus treatment updates — Atom
- Bacteremia caused by Staphylococcus aureus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Bacteremia caused by Staphylococcus aureus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacteremia-caused-by-staphylococcus-aureus. Accessed 2026-06-11.
Related
- Bacteremia caused by Staphylococcus aureus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing